Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01850563 · ClinicalTrials.gov registry record · NA

A Proof-of-principle Study of HBO-SRS for Brain Metastases

A NA study, sponsored by Dartmouth-Hitchcock Medical Center.

Completed
Registry status
NA
Development phase
22
Enrollment target

NCT01850563 is a NA study that has completed, run by Dartmouth-Hitchcock Medical Center. The registered enrollment target is 22 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01850563, a NA study, has completed, sponsored by Dartmouth-Hitchcock Medical Center.

COMPLETED
Registry status
NA
Development phase
22 participants
Enrollment target

Study Summary

Patients with brain metastases who are candidates for treatment with stereotactic radiosurgery (SRS) are potential study participants. SRS delivers high-energy, precisely-focused radiation to each brain metastasis to shrink the tumor, and is the standard-of-care for patients with these tumors. Oxygen enhances the damaging effects of radiation on tumor cells. Hyperbaric oxygen (HBO) therapy increases oxygen levels in all kinds of tissues, including tumors. The purpose of this trial is to study whether it is feasible to treat patients with HBO just prior to receiving SRS, given the timing constraints of treating sequentially with HBO and then SRS. Patients will undergo HBO treatment followed by the placement of a Gill-Thomas-Cosman head frame then transported ,via stretcher, to receive SRS. The transfer and placement of the head frame needs to be completed within the 15minute time frame. The trial's secondary objectives are to determine whether it has any effects on outcomes and quality of life. As part of study participation patients will be asked to complete quality of life questionnaires as well as mini mental status questionnaires. These will be done prior to treatment and at follow up appointments throughout the next 3 years while participating in the study. Patients will be given the option to participate in the optional bio marker blood draw study which would require patients to have blood drawn at three time points, pre-treatment, the day after treatment and at their first follow up visit.

Interventions

  • DEVICE Hyperbaric oxygen given at 2.4 ATA for 30 minutes immediately prior to SRS - HBOT for 30 minutes - SRS without prior HBO

Trial Details

FieldValue
Enrollment Target 22 participants
Start Date 2013-07-01
Est. Completion 2020-02-28
Phase NA

Sponsor

Dartmouth-Hitchcock Medical Center

427 total trials

What the Registry Record Tells You About NCT01850563

The ClinicalTrials.gov registry entry for NCT01850563 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 22 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Dartmouth-Hitchcock Medical Center, which has 427 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 1 intervention - of which Hyperbaric oxygen given at 2.4 ATA for 30 minutes immediately prior to SRS - HBOT for 30 minutes - SRS without prior HBO is the first listed.

NCT01850563 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT01850563 about?

NCT01850563 is a clinical study titled "A Proof-of-principle Study of HBO-SRS for Brain Metastases". Patients with brain metastases who are candidates for treatment with stereotactic radiosurgery (SRS) are potential study participants. SRS delivers high-energy, precisely-focused radiation to each brain metastasis to shrink the tumor, and is the standard-of-care for patients with these tumors. Oxyge...

What is the current status of trial NCT01850563?

This trial is currently completed. It is a NA study. The enrollment target is 22 participants. The study started on 2013-07-01. Estimated completion is 2020-02-28.

What interventions are being tested in trial NCT01850563?

The interventions under investigation include: Hyperbaric oxygen given at 2.4 ATA for 30 minutes immediately prior to SRS - HBOT for 30 minutes - SRS without prior HBO (DEVICE).

Who is sponsoring clinical trial NCT01850563?

This trial is sponsored by Dartmouth-Hitchcock Medical Center, which has 427 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.